GlobeImmune

GlobeImmune, Inc. was a clinical-stage biopharmaceutical company headquartered in Louisville, Colorado. Its research focused on therapeutic vaccines rather than preventive vaccines, with the stated objective of stimulating the immune system to recognize and eliminate diseased cells. The company’s principal technology was the Tarmogen platform, which used genetically modified yeast engineered to express one or more disease-associated antigens. These yeast-based products were designed to activate antigen-specific T-cell responses against cells carrying the corresponding target. The company’s development work covered oncology and infectious disease indications. Its oncology pipeline included candidates such as GI-4000, GI-4774, GI-6207, and GI-6301, while GI-5005 and other programs were associated with therapeutic vaccination approaches for hepatitis B and related infectious-disease applications. As a clinical-stage organization, GlobeImmune had not established a marketed-product business in the period described by the available reference material. Its operations therefore depended on research financing, strategic collaborations, and the progression of investigational products through clinical trials. GlobeImmune formed a cancer-vaccine collaboration with Celgene in 2009 and also worked with the National Cancer Institute. It separately collaborated with Gilead on therapeutic vaccines for hepatitis B. That Gilead relationship ended in November 2016 after the relevant development program failed a clinical trial in 2015. The failure illustrated the clinical and financial risks associated with the company’s strategy: promising platform science had to be converted into demonstrable clinical benefit before any program could generate commercial value. The company raised $17.5 million through a Series E preferred-stock financing in January 2010. Because GlobeImmune had no marketed products during the period covered by the cited material, financing and partnerships were important sources of support for its continuing research and development. In July 2015, following the failure of a trial involving GI-4774, the company announced plans to eliminate most workforce positions. At that time, two other therapeutic-vaccine candidates, GI-6207 and GI-6301, were reported to remain in clinical trials, while trials of GI-4000 and GI-5005 had been completed. In March 2017, GlobeImmune announced that it had entered into a definitive agreement to sell shares of its common stock to NantCell, Inc. The available material does not establish the final completion terms, the company’s subsequent operating status, or whether the transaction resulted in a full change of control. Accordingly, GlobeImmune’s current ownership, product portfolio, website, leadership, and status cannot be confirmed from the supplied sources. Its documented identity is that of a clinical-stage vaccine developer whose central business proposition was the use of engineered yeast to generate targeted cellular immune responses in cancer and infectious disease.

GlobeImmune developed therapeutic vaccines for cancer and infectious diseases and was based in Louisville, Colorado. Its central scientific approach was the Tarmogen platform. Tarmogens were produced from genetically modified yeast cells engineered to express disease-associated antigens. The intended mechanism was to stimulate T cells that could identify and destroy diseased cells presenting the same antigens. This approach placed GlobeImmune within the therapeutic-vaccine and immuno-oncology sectors rather than the conventional preventive-vaccine market. The company pursued multiple clinical programs. GI-4000 was described as its leading oncology candidate around 2010, and the broader oncology pipeline included GI-4774, GI-6207, and GI-6301. The company also developed GI-5005 and related programs for infectious disease, including hepatitis B. The available material indicates that GlobeImmune had no marketed products as of August 2014, meaning that its activities remained centered on research, clinical testing, partnering, and capital formation. GlobeImmune established a cancer-vaccine partnership with Celgene in 2009 and collaborated with the National Cancer Institute. A separate relationship with Gilead concerned therapeutic vaccines for hepatitis B. That collaboration was terminated in November 2016 after the product under development failed a clinical trial during the preceding year. The termination reduced the company’s externally partnered development activity and followed a series of clinical setbacks. The company financed its operations through investment rather than product revenue. In January 2010, it raised $17.5 million in a Series E preferred-stock financing. By August 2015, GI-6207 and GI-6301 were reported to be in clinical trials, while trials involving GI-4000 and GI-5005 had been completed. In July 2015, after the failure of a GI-4774 trial, GlobeImmune announced that it would eliminate most of its workforce positions. This restructuring reflected the pressure placed on a clinical-stage biotechnology company when a key development program does not produce a successful result. In March 2017, GlobeImmune announced a definitive purchase agreement for the sale of shares of its common stock to NantCell, Inc. The supplied reference does not document whether the agreement closed, the resulting ownership structure, or GlobeImmune’s activities after the announcement. It also does not establish a current website, current management team, active product portfolio, or present corporate status. The company should therefore be treated as a historically documented clinical-stage biotechnology brand with an uncertain current status.

1. 2017NantCell stock-purchase agreement announced

   GlobeImmune announced a definitive agreement to sell shares of its common stock to NantCell, Inc.

   Source
2. 2016Gilead hepatitis B collaboration terminated

   The collaboration with Gilead on therapeutic hepatitis B vaccines ended after the associated product failed a clinical trial in 2015.

   Source
3. 2015GI-4774 clinical-trial failure and workforce reduction

   After a GI-4774 trial failed, GlobeImmune announced plans to eliminate most workforce positions. GI-6207 and GI-6301 remained in clinical trials during the period described.

   Source
4. 2014No marketed products reported

   Reference material reported that GlobeImmune had no marketed products as of August 2014.

   Source
5. 2010Series E financing

   The company raised $17.5 million through a Series E preferred-stock offering.

   Source
6. 2009Cancer-vaccine collaboration with Celgene

   GlobeImmune established a collaboration with Celgene for the development of cancer vaccines.

   Source

A clinical-stage biotechnology developer positioned around therapeutic vaccination and antigen-specific T-cell activation, using genetically modified yeast to target cancer and infectious-disease antigens.

• TarmogenImmunotherapy platform

  Tarmogen was GlobeImmune’s platform for therapeutic vaccines made from genetically modified yeast. The yeast was engineered to express one or more disease-associated antigens. The intended biological effect was activation of T cells capable of recognizing and eliminating diseased cells that carried the same target antigen. The platform was applied to both oncology and infectious-disease development programs.

• GI-4000Therapeutic cancer vaccine

  GI-4000 was an oncology candidate developed through GlobeImmune’s Tarmogen platform. It was identified as the company’s lead oncology candidate around 2010 and was evaluated as an investigational therapeutic vaccine intended to generate an immune response against disease-associated cancer antigens. The available material does not provide a final development outcome or commercial status.

• GI-4774Therapeutic cancer vaccine

  GI-4774 was an investigational therapeutic-vaccine candidate in GlobeImmune’s oncology pipeline. A clinical trial examining the candidate failed, and the result was followed by the company’s July 2015 announcement that it would eliminate most workforce positions. No marketed product or later development status is established in the supplied material.

• GI-6207Therapeutic cancer vaccine

  GI-6207 was one of the GlobeImmune therapeutic vaccines reported to be in clinical trials as of August 2015. It represented the company’s effort to use the Tarmogen platform in cancer treatment. The supplied sources do not identify its target indication, later trial results, licensing outcome, or commercial availability.

• GI-6301Therapeutic cancer vaccine

  GI-6301 was an investigational therapeutic vaccine in GlobeImmune’s oncology pipeline. It was reported as being in clinical trials in August 2015, alongside GI-6207. Further information about its disease target, efficacy, safety, partnership status, and subsequent development is not established by the supplied reference.

• GI-5005Therapeutic infectious-disease vaccine

  GI-5005 was an investigational therapeutic-vaccine program associated with GlobeImmune’s infectious-disease work. The company’s broader hepatitis B vaccine activities were conducted in collaboration with Gilead, although the relevant collaboration was later terminated after a clinical-trial failure. The supplied sources do not conclusively connect every GI-5005 development detail to that termination or provide a final product status.

• 2017Agreement to sell common-stock shares to NantCellM&A

  As a clinical-stage company without documented marketed products, GlobeImmune announced a transaction involving its common stock.

  What changed. In March 2017, GlobeImmune announced that it had entered into a definitive purchase agreement for the sale of common-stock shares to NantCell, Inc.

  Aftermath. The available reference does not confirm closing, the final ownership structure, transaction consideration, or GlobeImmune’s later corporate status.

  Source
• 2016Termination of Gilead hepatitis B collaborationOther

  GlobeImmune and Gilead had been developing therapeutic vaccines for hepatitis B, but the relevant product failed a clinical trial in 2015.

  What changed. The collaboration was terminated in November 2016.

  Aftermath. The end of the collaboration removed a major external development relationship from GlobeImmune’s infectious-disease activities. No subsequent commercial outcome is provided.

  Source
• 2015Workforce reduction after GI-4774 trial failureStrategy

  A clinical trial evaluating GI-4774 failed, increasing pressure on GlobeImmune’s clinical-stage business and financing model.

  What changed. In July 2015, the company announced that it would eliminate most of its workforce positions while selected clinical programs continued.

  Aftermath. The restructuring followed a major pipeline setback. The supplied material does not quantify the number of affected employees or document the company’s subsequent operating results.

  Source

• 2017GlobeImmune agrees to sell common-stock shares to NantCell

  GlobeImmune announced a definitive purchase agreement under which NantCell, Inc. would acquire shares of GlobeImmune common stock. The supplied reference does not provide final transaction details or confirm completion.

  M&A
  Source
• 2016Gilead collaboration for hepatitis B vaccines ends

  GlobeImmune’s collaboration with Gilead on therapeutic vaccines for hepatitis B was terminated after the associated product failed a clinical trial in 2015.

  Other
  Source
• 2015GlobeImmune announces workforce reductions after GI-4774 trial failure

  Following the failure of a clinical trial evaluating GI-4774, GlobeImmune announced that it would eliminate most workforce positions while continuing selected development programs.

  Other
  Source
• 2010GlobeImmune raises $17.5 million in Series E preferred-stock financing

  The company raised $17.5 million through a Series E preferred-stock offering to support its clinical-stage development activities.

  Other
  Source

1. GlobeImmune